Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Daiichi Sankyo S/Adr (OP:DSNKY)

19.30 +0.36 (+1.90%)
Streaming Delayed Price Updated: 3:51 PM EST, Feb 24, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 316,776
Open 19.20
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 18.94
Today's Range 19.12 - 19.32
52wk Range 17.80 - 28.21
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Biotech Sector Soars: Promising Drug Trials Ignite Investor Confidence and Spark Market Rally
The biotech sector is currently experiencing a robust rally, a significant turnaround from a period of subdued performance. This resurgence is primarily fueled by a wave of promising drug trial results... 
Via MarketMinute
Topics Artificial Intelligence Intellectual Property
News headline image
FDA Approves AstraZeneca And Daiichi Sankyo's Datroway For EGFR-Mutated Lung Cancer ↗
FDA grants accelerated approval to AstraZeneca's Datroway for EGFR-mutant NSCLC after prior therapies, with a 45% response rate and a $45 million milestone due. 
Via Benzinga

Performance

YTD
-9.7%
-9.7%
1 Month
-4.7%
-4.7%
3 Month
-21.7%
-21.7%
6 Month
-21.3%
-21.3%
1 Year
-14.8%
-14.8%

More News

Read More
News headline image
AstraZeneca- Daiichi Sankyo's Multi-Billion Dollar Cancer Drug Shows Superior Efficacy Across Broad HER2 Positive Metastatic Breast Cancer Patients ↗
Via Benzinga
News headline image
DSNKY Stock Earnings: Daiichi Sankyo Co Reported Results for Q1 2024 ↗
Via InvestorPlace
News headline image
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed ↗
Via Benzinga
News headline image
FDA Approves AstraZeneca, Daiichi Sankyo's Enhertu For Certain Type Of Breast Cancer Patients ↗
Via Benzinga
News headline image
FDA Approves AstraZeneca's Datroway For Pretreated Breast Cancer Patients ↗
Via Benzinga
News headline image
After Lung Cancer Approval, AstraZeneca's Imfinzi Goes Under FDA Priority Review For Bladder Cancer ↗
Via Benzinga
News headline image
Latest Trial Setback For AstraZeneca's Dato-DXd, The Drug Fails To Extend Lives Of Pretreated Breast Cancer Patients ↗
Via Benzinga
News headline image
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study ↗
Via Benzinga
News headline image
AstraZeneca's Investigational Cancer Drug Disappoints In Late-Stage Lung Cancer Trial ↗
Via Benzinga
News headline image
Is Merck Stock Undervalued After Its Colossal Earnings Growth?
Via MarketBeat
News headline image
Recession-Resilient Asian Stock Picks: TSMC, SK Hynix Among This Analyst's Top 10 ↗
Via Benzinga
News headline image
Merck's Q2 Earnings: Revenue And EPS Beat Helped By Strong Keytruda Sales, But Acquisition Costs Bites Into Annual Profit Forecast ↗
Via Benzinga
News headline image
The 3 Most Undervalued Nasdaq 100 Stocks to Buy in July 2024 ↗
Via InvestorPlace
News headline image
FDA Declines To Approve Merck-Daiichi Sankyo Partnered Lung Cancer Drug ↗
Via Benzinga
News headline image
Why Is AstraZeneca Stock Trading Lower On Tuesday? ↗
Via Benzinga
News headline image
DSNKY Stock Earnings: Daiichi Sankyo Co Reported Results for Q3 2023 ↗
Via InvestorPlace
News headline image
Double Good News For AstraZeneca's Breast Cancer Drugs ↗
Via Benzinga
News headline image
AstraZeneca/Daiichi's Flagship Drug Enhertu Secures Accelerated FDA Approval For Pretreated Cancer Patients With Solid Tumor ↗
Via Benzinga
News headline image
What's Going On With Pfizer Stock Today? ↗
Via Benzinga
News headline image
Why Pharmaceutical Company Esperion Therapeutics Shares Are Diving Today ↗
Via Benzinga
News headline image
Japan Emerges As Promising 2024 Investment Destination: 3 Stocks To Consider ↗
Via Benzinga
News headline image
Merck Just Made a Big Move -- but Will It Be Enough for Investors Right Now? ↗
Via The Motley Fool
News headline image
Better Than Chemotherapy - AstraZeneca/Daiichi Sankyo Partnered Cancer Drug Meets Primary Goal In Breast Cancer Setting ↗
Via Benzinga

Frequently Asked Questions

Is Daiichi Sankyo S/Adr publicly traded?
Yes, Daiichi Sankyo S/Adr is publicly traded.
What exchange does Daiichi Sankyo S/Adr trade on?
Daiichi Sankyo S/Adr trades on the OTC Traded
What is the ticker symbol for Daiichi Sankyo S/Adr?
The ticker symbol for Daiichi Sankyo S/Adr is DSNKY on the OTC Traded
What is the current price of Daiichi Sankyo S/Adr?
The current price of Daiichi Sankyo S/Adr is 19.30
When was Daiichi Sankyo S/Adr last traded?
The last trade of Daiichi Sankyo S/Adr was at 02/24/26 03:51 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.